- Home
- SONO vs SDGR Comparison
SONO vs SDGR Comparison
Compare SONO & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- SDGR
- Stock Information
- Founded
- SONO 2002
- SDGR 1990
- Country
- SONO United States
- SDGR United States
- Employees
- SONO N/A
- SDGR N/A
- Industry
- SONO Consumer Electronics/Video Chains
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- SDGR Health Care
- Exchange
- SONO Nasdaq
- SDGR Nasdaq
- Market Cap
- SONO 1.8B
- SDGR 1.6B
- IPO Year
- SONO 2018
- SDGR 2020
- Fundamental
- Price
- SONO $14.00
- SDGR $19.00
- Analyst Decision
- SONO Buy
- SDGR Buy
- Analyst Count
- SONO 2
- SDGR 10
- Target Price
- SONO $17.50
- SDGR $32.90
- AVG Volume (30 Days)
- SONO 2.0M
- SDGR 624.0K
- Earning Date
- SONO 02-06-2025
- SDGR 02-26-2025
- Dividend Yield
- SONO N/A
- SDGR N/A
- EPS Growth
- SONO N/A
- SDGR N/A
- EPS
- SONO N/A
- SDGR N/A
- Revenue
- SONO $1,518,056,000.00
- SDGR $193,348,000.00
- Revenue This Year
- SONO N/A
- SDGR N/A
- Revenue Next Year
- SONO $8.82
- SDGR $26.50
- P/E Ratio
- SONO N/A
- SDGR N/A
- Revenue Growth
- SONO N/A
- SDGR N/A
- 52 Week Low
- SONO $10.23
- SDGR $16.67
- 52 Week High
- SONO $19.76
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- SONO 41.24
- SDGR 43.08
- Support Level
- SONO $13.89
- SDGR $18.63
- Resistance Level
- SONO $15.01
- SDGR $20.20
- Average True Range (ATR)
- SONO 0.55
- SDGR 1.00
- MACD
- SONO -0.15
- SDGR -0.15
- Stochastic Oscillator
- SONO 41.25
- SDGR 19.14
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.